The US Food and Drug Administration has told genetics company 23andMe to stop selling its Personal Genome Service product immediately.
Medical company Scion Biomedical Inc has launched a lawsuit accusing a senior employee of breaching trade secrets to file a patent for her new start-up company.
The IPAB has revoked US probiotic dietary supplement maker Kibow Biotech’s Indian patent covering a formulation used to increase kidney function.
The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.
Cadence Pharmaceuticals announced on November 14 that the US District Court for the District of Delaware ruled in its favour in its patent infringement suit against Exela Pharma Sciences LLC.
Kevin Mooney, chairman of the drafting committee for the Unified Patent Court (UPC)’s rules of procedure, explained the current state of play to the CIPA Life Sciences conference.
The EPO boards of appeal are unlikely to be able to reduce the case backlog anytime soon, but attorneys should be wary of possible changes in board practice, former board head Alec Clelland told the CIPA Life Sciences conference.
Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.
The FTC has issued final changes to the premerger notification rules that require pharmaceutical companies to report certain proposed patent right acquisitions to the commission and US Department of Justice for antitrust review.
The US District Court for the Northern District of California has dismissed biosimilar maker Sandoz’s motion for declaratory judgment that its etanercept product does not infringe biopharmaceutical company Amgen’s arthritis drug Enbrel.